$BBIO
BridgeBio Pharma, Inc. Stock $bbio

$bbio Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023004145 Filed on February 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.826M	$1.870M	$77.65M
YoY Change	7.79%	-85.49%	11.38%
Cost Of Revenue	$651.0K	$647.0K	$3.434M
YoY Change	-51.71%	-58.28%	25.56%
Gross Profit	$1.175M	$1.223M	$74.21M
YoY Change	239.6%	-89.21%	10.8%
Gross Profit Margin	64.35%	65.4%	95.58%
Selling, General & Admin	$31.11M	$31.86M	$143.2M
YoY Change	-28.84%	-41.8%	-25.5%
% of Gross Profit	2647.49%	2605.23%	192.94%
Research & Development	$92.86M	$90.90M	$399.5M
YoY Change	-13.74%	-25.61%	-11.43%
% of Gross Profit	7903.06%	7432.71%	538.26%
Depreciation & Amortization	$1.633M	$1.660M	$6.771M
YoY Change	-13.32%	8.78%	15.88%
% of Gross Profit	138.98%	135.73%	9.12%
Operating Expenses	$124.0M	$122.8M	$542.7M
YoY Change	-18.1%	-30.62%	-15.64%
Operating Profit	-$126.2M	-$121.5M	-$512.2M
YoY Change	-27.36%	-26.61%	-11.17%
Interest Expense	$20.12M	-$15.90M	$80.44M
YoY Change	-1.1%	6.33%	71.96%
% of Operating Profit
Other Income/Expense, Net	-$16.57M	$4.560M	$27.55M
YoY Change	-40.08%	-83.88%	-380.49%
Pretax Income	-$142.7M	-$140.6M	-$485.1M
YoY Change	-29.11%	-7.69%	-17.29%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$142.7M	-$137.6M	-$484.7M
YoY Change	-29.11%	-6.51%	-17.36%
Net Earnings / Revenue	-7816.65%	-7357.81%	-624.17%
Basic Earnings Per Share	-$0.92		-$3.26
Diluted Earnings Per Share	-$0.92	-$0.92	-$3.26
COMMON SHARES
Basic Shares Outstanding	151.4M	149.5M	147.5M
Diluted Shares Outstanding	152.6M		147.5M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$491.3M	$471.9M	$471.9M
YoY Change	-26.81%	-43.59%	-43.59%
Cash & Equivalents	$407.4M	$376.7M	$376.7M
Short-Term Investments	$83.93M	$95.23M	$95.23M
Other Short-Term Assets	$61.41M	$76.93M	$76.93M
YoY Change	36.45%	47.39%	47.39%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$552.7M	$548.9M	$548.9M
YoY Change	-22.83%	-38.25%	-38.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.57M	$14.57M	$25.25M
YoY Change	-21.05%	-51.54%	-45.08%
Goodwill
YoY Change
Intangibles	$28.11M	$28.71M
YoY Change	-7.75%	-36.1%
Long-Term Investments
YoY Change
Other Assets	$20.77M	$20.22M	$20.22M
YoY Change	-41.21%	-38.77%	-38.77%
Total Long-Term Assets	$72.98M	$74.18M	$74.18M
YoY Change	-24.7%	-40.14%	-40.14%
TOTAL ASSETS
Total Short-Term Assets	$552.7M	$548.9M	$548.9M
Total Long-Term Assets	$72.98M	$74.18M	$74.18M
Total Assets	$625.7M	$623.0M	$623.0M
YoY Change	-23.05%	-38.48%	-38.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.076M	$11.56M	$11.56M
YoY Change	-59.67%	-2.74%	-2.74%
Accrued Expenses	$85.85M	$101.7M	$101.7M
YoY Change	-8.05%	-17.23%	-17.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$96.60M	$121.4M	$121.4M
YoY Change	-6.64%	-10.1%	-10.1%
LONG-TERM LIABILITIES
Long-Term Debt	$435.8M	$431.0M	$1.708B
YoY Change	0.38%	0.06%	0.15%
Other Long-Term Liabilities	$17.50M	$26.64M	$38.92M
YoY Change	-34.77%	20.73%	1.74%
Total Long-Term Liabilities	$453.3M	$457.6M	$1.747B
YoY Change	-1.67%	1.06%	0.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$96.60M	$121.4M	$121.4M
Total Long-Term Liabilities	$453.3M	$457.6M	$1.747B
Total Liabilities	$1.839B	$1.868B	$1.878B
YoY Change	-0.78%	-0.55%	-0.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.057B	-$1.918B
YoY Change	25.96%	33.49%
Common Stock	$1.107B	$938.9M
YoY Change	27.55%	11.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$275.0M	$275.0M
YoY Change	0.0%	0.0%
Treasury Stock Shares	$6.192M	$6.192M
Shareholders Equity	-$1.226B	-$1.255B	-$1.255B
YoY Change
Total Liabilities & Shareholders Equity	$625.7M	$623.0M	$623.0M
YoY Change	-23.05%	-38.48%	-38.48%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$142.7M	-$137.6M	-$484.7M
YoY Change	-29.11%	-6.51%	-17.36%
Depreciation, Depletion And Amortization	$1.633M	$1.660M	$6.771M
YoY Change	-13.32%	8.78%	15.88%
Cash From Operating Activities	-$144.3M	-$93.24M	-$419.5M
YoY Change	-10.16%	-30.36%	-15.75%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	$801.0K	$4.821M
YoY Change	-98.6%	-131.59%	-63.6%
Acquisitions
YoY Change
Other Investing Activities	$12.31M	$18.77M	$0.00
YoY Change	-91.17%	-22.89%	-100.0%
Cash From Investing Activities	$12.30M	$17.96M	$453.1M
YoY Change	-91.13%	-17.59%	-325.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$4.852M
YoY Change			-102.43%
Debt Paid & Issued, Net	$0.00		$20.49M
YoY Change			-83.49%
Cash From Financing Activities	150.2M	6.377M	-13.13M
YoY Change	-94005.63%	-98.04%	-101.78%
NET CHANGE
Cash From Operating Activities	-144.3M	-93.24M	-419.5M
Cash From Investing Activities	12.30M	17.96M	453.1M
Cash From Financing Activities	150.2M	6.377M	-13.13M
Net Change In Cash	18.23M	-68.90M	20.52M
YoY Change	-182.2%	-132.3%	-45.55%
FREE CASH FLOW
Cash From Operating Activities	-$144.3M	-$93.24M	-$419.5M
Capital Expenditures	$12.00K	$801.0K	$4.821M
Free Cash Flow	-$144.3M	-$94.04M	-$424.3M
YoY Change	-10.63%	-28.41%	-16.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001743881
CY2022Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38959
CY2022	dei	Entity Registrant Name EntityRegistrantName	BridgeBio Pharma, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1850815
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3160 Porter Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94304
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	391-9740
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	BBIO
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	976800000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	151373044
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	San Francisco, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376689000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51580000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	393743000
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	43653000
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	49148000
CY2022Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	17079000
CY2021Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	19749000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	177000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	37930000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	156817333
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150625572
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21922000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32269000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	548853000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	888858000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14569000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30066000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10678000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15907000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28712000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44934000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20224000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33027000
CY2022Q4	us-gaap	Assets Assets	623036000
CY2021Q4	us-gaap	Assets Assets	1012792000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11558000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11884000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31256000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	37041000
CY2022Q4	bbio	Accrued Research And Development Liabilities Current AccruedResearchAndDevelopmentLiabilitiesCurrent	39803000
CY2021Q4	bbio	Accrued Research And Development Liabilities Current AccruedResearchAndDevelopmentLiabilitiesCurrent	44138000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1790000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6786000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3675000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4938000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8156000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25190000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30282000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	121428000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	135069000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430993000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430752000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12274000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17428000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26643000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22069000
CY2022Q4	us-gaap	Liabilities Liabilities	1867960000
CY2021Q4	us-gaap	Liabilities Liabilities	1878371000
CY2022Q4	bbio	Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests	-1589000
CY2021Q4	bbio	Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests	1423000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153535084
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147343323
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	157000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	154000
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	6191761
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	6191761
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	275000000
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	275000000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	938703000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	841530000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-328000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-132000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1918149000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1436966000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1254617000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-870414000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	11282000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	3412000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1243335000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-867002000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	623036000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1012792000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77648000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69716000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8249000
CY2022	bbio	Cost Of License Revenue And Products Sold CostOfLicenseRevenueAndProductsSold	3434000
CY2021	bbio	Cost Of License Revenue And Products Sold CostOfLicenseRevenueAndProductsSold	3114000
CY2020	bbio	Cost Of License Revenue And Products Sold CostOfLicenseRevenueAndProductsSold	0
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	399462000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	451024000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	337047000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	143189000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	192210000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	145684000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	43765000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0
CY2020	us-gaap	Restructuring Charges RestructuringCharges	0
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	589850000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	646348000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	482731000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-512202000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-576632000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-474482000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	7542000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1133000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	4015000
CY2021	bbio	Gain From Sale Of Priority Review Voucher Net GainFromSaleOfPriorityReviewVoucherNet	0
CY2020	bbio	Gain From Sale Of Priority Review Voucher Net GainFromSaleOfPriorityReviewVoucherNet	0
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7500000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35823000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1634000
CY2022	us-gaap	Interest Expense InterestExpense	80438000
CY2021	us-gaap	Interest Expense InterestExpense	46778000
CY2020	us-gaap	Interest Expense InterestExpense	36655000
CY2022	bbio	Gain From Sale Of Priority Review Voucher Net GainFromSaleOfPriorityReviewVoucherNet	107946000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27550000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9822000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31006000
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3469000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-23915000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56764000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-481183000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-562539000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-448724000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.26
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.26
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.90
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.90
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.80
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.80
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147473076
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147473076
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144356619
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144356619
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117995457
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117995457
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-196000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-324000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-62000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-484848000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-586778000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-505550000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3469000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-23915000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-56764000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-481379000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-562863000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-448786000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	473733000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36530000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	168078000
CY2020	bbio	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	-49280000
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	75000000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-62000
CY2020	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	50828000
CY2020	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-1843000
CY2020	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-500930000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106256000
CY2021Q4	bbio	Repurchase Of Noncontrolling Interests Transaction Costs RepurchaseOfNoncontrollingInterestsTransactionCosts	70734000
CY2021	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-91997000
CY2021	bbio	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	-61295000
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	200000000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89823000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-324000
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4727000
CY2021	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	6240000
CY2021	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	3455000
CY2021	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-581129000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-867002000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94173000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4852000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-196000
CY2022	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	4815000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-604000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7092000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1225000
CY2022	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	-15169000
CY2022	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-2399000
CY2022	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-479241000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1243335000
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	91559000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	99505000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	58459000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6771000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5843000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1456000
CY2022	bbio	Noncash Lease Expense NoncashLeaseExpense	5172000
CY2021	bbio	Noncash Lease Expense NoncashLeaseExpense	5611000
CY2020	bbio	Noncash Lease Expense NoncashLeaseExpense	3088000
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-8222000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	29914000
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2022	bbio	Gain From Sale Of Priority Review Voucher Excluding Transaction Costs GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts	110000000
CY2021	bbio	Gain From Sale Of Priority Review Voucher Excluding Transaction Costs GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts	0
CY2020	bbio	Gain From Sale Of Priority Review Voucher Excluding Transaction Costs GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts	0
CY2022	bbio	Accrual Of Payment In Kind Interest On Term Loan AccrualOfPaymentInKindInterestOnTermLoan	13562000
CY2021	bbio	Accrual Of Payment In Kind Interest On Term Loan AccrualOfPaymentInKindInterestOnTermLoan	0
CY2020	bbio	Accrual Of Payment In Kind Interest On Term Loan AccrualOfPaymentInKindInterestOnTermLoan	0
CY2022	bbio	Gain From Recognition Of Receivable From Licensing And Collaboration Agreements GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements	12500000
CY2021	bbio	Gain From Recognition Of Receivable From Licensing And Collaboration Agreements GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements	0
CY2020	bbio	Gain From Recognition Of Receivable From Licensing And Collaboration Agreements GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements	0
CY2022	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	4567000
CY2021	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	0
CY2020	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	6014000
CY2022	us-gaap	Accretion Expense AccretionExpense	8570000
CY2021	us-gaap	Accretion Expense AccretionExpense	5795000
CY2020	us-gaap	Accretion Expense AccretionExpense	17737000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1571000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1197000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3338000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-6261000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12720000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	bbio	Call Option Expense Income CallOptionExpenseIncome	0
CY2021	bbio	Call Option Expense Income CallOptionExpenseIncome	-5550000
CY2020	bbio	Call Option Expense Income CallOptionExpenseIncome	1472000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	19749000
CY2020	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	0
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	0
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	0
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7059000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10971000
CY2020	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-2845000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9816000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2146000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-349000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2833000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3337000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7671000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4262000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-735000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2362000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	7378000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8589000
CY2022	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	-4309000
CY2021	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	11178000
CY2020	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	6170000
CY2022	bbio	Increase Decrease In Accrued Professional Service IncreaseDecreaseInAccruedProfessionalService	-4996000
CY2021	bbio	Increase Decrease In Accrued Professional Service IncreaseDecreaseInAccruedProfessionalService	2157000
CY2020	bbio	Increase Decrease In Accrued Professional Service IncreaseDecreaseInAccruedProfessionalService	2407000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6245000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6122000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3472000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	15262000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2733000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	12007000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8335000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-419494000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-497934000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-399714000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	137493000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	589892000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	287852000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	479688000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	380200000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	249137000
CY2022	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0
CY2021	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	62691000
CY2020	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	55562000
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	53383000
CY2020	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	52835000
CY2021	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	34150000
CY2020	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	0
CY2022	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	0
CY2021	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	13654000
CY2020	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	0
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1500000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	35000000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2022	bbio	Proceeds From Sale Of Priority Review Voucher Excluding Transaction Cost ProceedsFromSaleOfPriorityReviewVoucherExcludingTransactionCost	110000000
CY2021	bbio	Proceeds From Sale Of Priority Review Voucher Excluding Transaction Cost ProceedsFromSaleOfPriorityReviewVoucherExcludingTransactionCost	0
CY2020	bbio	Proceeds From Sale Of Priority Review Voucher Excluding Transaction Cost ProceedsFromSaleOfPriorityReviewVoucherExcludingTransactionCost	0
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	10000000
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4821000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13246000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7518000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	6760000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	453147000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200826000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52993000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	747500000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	550000000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	16064000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13039000
CY2022	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	0
CY2021	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	61295000
CY2020	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	49280000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	200000000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	75000000
CY2022	bbio	Proceeds From Issuance Of Noncontrolling Interest ProceedsFromIssuanceOfNoncontrollingInterest	0
CY2021	bbio	Proceeds From Issuance Of Noncontrolling Interest ProceedsFromIssuanceOfNoncontrollingInterest	3500000
CY2020	bbio	Proceeds From Issuance Of Noncontrolling Interest ProceedsFromIssuanceOfNoncontrollingInterest	2000000
CY2022	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	0
CY2021	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	85090000
CY2020	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	0
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	456296000
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	20486000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	124119000
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2558000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3821000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1205000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1561000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4746000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	714000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	666000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16643000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12923000
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	24094000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4852000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5000000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	837000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13134000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	736446000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	447189000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20519000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37686000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5518000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	364197000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	416884000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	54443000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	29774000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	15322000
CY2022	bbio	Payment In Kind Interest Added To Principal Of Term Loan PaymentInKindInterestAddedToPrincipalOfTermLoan	1763000
CY2021	bbio	Payment In Kind Interest Added To Principal Of Term Loan PaymentInKindInterestAddedToPrincipalOfTermLoan	0
CY2020	bbio	Payment In Kind Interest Added To Principal Of Term Loan PaymentInKindInterestAddedToPrincipalOfTermLoan	0
CY2022	bbio	Deferred Merger Transaction Costs Included In Accounts Payable And Accrued Professional Services DeferredMergerTransactionCostsIncludedInAccountsPayableAndAccruedProfessionalServices	0
CY2021	bbio	Deferred Merger Transaction Costs Included In Accounts Payable And Accrued Professional Services DeferredMergerTransactionCostsIncludedInAccountsPayableAndAccruedProfessionalServices	0
CY2020	bbio	Deferred Merger Transaction Costs Included In Accounts Payable And Accrued Professional Services DeferredMergerTransactionCostsIncludedInAccountsPayableAndAccruedProfessionalServices	1842000
CY2022	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0
CY2021	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	2449000
CY2020	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0
CY2022	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-3512000
CY2021	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-2124000
CY2020	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	12034000
CY2022	bbio	Recognition Of Property And Equipment Previously Classified In Other Assets RecognitionOfPropertyAndEquipmentPreviouslyClassifiedInOtherAssets	0
CY2021	bbio	Recognition Of Property And Equipment Previously Classified In Other Assets RecognitionOfPropertyAndEquipmentPreviouslyClassifiedInOtherAssets	0
CY2020	bbio	Recognition Of Property And Equipment Previously Classified In Other Assets RecognitionOfPropertyAndEquipmentPreviouslyClassifiedInOtherAssets	10000000
CY2022	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	0
CY2021	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	21600000
CY2020	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	4727000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	47000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	563000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1101000
CY2022	bbio	Recognized Intangible Asset Recorded In Other Accrued Liabilities And Other Long Term Liabilities RecognizedIntangibleAssetRecordedInOtherAccruedLiabilitiesAndOtherLongTermLiabilities	11000000
CY2021	bbio	Recognized Intangible Asset Recorded In Other Accrued Liabilities And Other Long Term Liabilities RecognizedIntangibleAssetRecordedInOtherAccruedLiabilitiesAndOtherLongTermLiabilities	12500000
CY2020	bbio	Recognized Intangible Asset Recorded In Other Accrued Liabilities And Other Long Term Liabilities RecognizedIntangibleAssetRecordedInOtherAccruedLiabilitiesAndOtherLongTermLiabilities	0
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1120000
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2022	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	0
CY2021	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	38168000
CY2020	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	0
CY2022	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	0
CY2021	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	8749000
CY2020	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	0
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376689000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	177000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	139000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2265000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2416000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2458000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	416884000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	356082000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	37930000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376689000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	356082000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	139000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	37930000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	177000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2265000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2416000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	358679000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Organization and Description of Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">BridgeBio Pharma, Inc. or BridgeBio or the Company, is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities, or VIEs for which BridgeBio is the primary beneficiary, or, collectively, we, our, or us. BridgeBio is headquartered in Palo Alto, California.</span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain reclassifications have been made to the consolidated statements of cash flows for the year ended December 31, 2020 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">to conform to the current year’s presentation. These reclassifications had no net effect on cash flows from operating, investing and financing activities as previously reported.</span></p>
CY2022	bbio	Minimum Required Percentage Of Voting Interests Of Investee To Exercise Significant Influence MinimumRequiredPercentageOfVotingInterestsOfInvesteeToExerciseSignificantInfluence	0.20
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">accruals for research and development activities and contingent clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions, </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">accruals for performance-based milestone compensation arrangements, </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">the expected recoverability and estimated useful lives of our long-lived assets, and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022	bbio	Cash Cash Equivalents And Restricted Cash Maturity Period CashCashEquivalentsAndRestrictedCashMaturityPeriod	P90D
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2458000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	416884000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4100000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3300000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	bbio	Number Of Business Segments NumberOfBusinessSegments	1
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	3731000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2206000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	11953000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	40830000
CY2022	bbio	Net Gains Losses Included In Other Income Expense Net NetGainsLossesIncludedInOtherIncomeExpenseNet	-8222000
CY2021	bbio	Net Gains Losses Included In Other Income Expense Net NetGainsLossesIncludedInOtherIncomeExpenseNet	29914000
CY2022Q4	bbio	Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2021Q4	bbio	Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2021Q4	bbio	Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2022Q4	bbio	Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2022	bbio	Gain From Conversion Of Equity Method Investment To Investment In Equity Securities GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities	0
CY2021	bbio	Gain From Conversion Of Equity Method Investment To Investment In Equity Securities GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities	68538000
CY2021Q1	bbio	Leo Call Option Liability Current LEOCallOptionLiabilityCurrent	0
CY2021	bbio	Call Option Expense Income CallOptionExpenseIncome	-5600000
CY2022Q4	bbio	Estimated Fair Value Of Outstanding Term Loan EstimatedFairValueOfOutstandingTermLoan	377200000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	2400000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	2400000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	362062000
CY2022Q4	bbio	Cash Equivalents Unrealized Gains CashEquivalentsUnrealizedGains	0
CY2022Q4	bbio	Cash Equivalents Unrealized Losses CashEquivalentsUnrealizedLosses	-54000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	362008000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	413916000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	328000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	413588000
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	233103000
CY2021Q4	bbio	Cash Equivalents Unrealized Gains CashEquivalentsUnrealizedGains	0
CY2021Q4	bbio	Cash Equivalents Unrealized Losses CashEquivalentsUnrealizedLosses	-2000
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	233101000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	626976000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	134000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	626844000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2022	bbio	Short Term Marketable Securities Contractual Maturities ShortTermMarketableSecuritiesContractualMaturities	P6M
CY2021	bbio	Short Term Marketable Securities Contractual Maturities ShortTermMarketableSecuritiesContractualMaturities	P6M
CY2022	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-3500000
CY2021	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-2100000
CY2020	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	12000000.0
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	600000
CY2021Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	2100000
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32500000
CY2021	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y9M18D
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47500000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3788000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2566000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28712000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44934000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	2400000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	2400000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	19100000
CY2022Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Stock PotentialMilestoneFixedMonetaryAmountSettlementInStock	60558000
CY2022Q4	bbio	Potential Milestone Accrued Amount Settlement In Stock PotentialMilestoneAccruedAmountSettlementInStock	9716000
CY2022Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion	103072000
CY2022Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Cash PotentialMilestoneFixedMonetaryAmountSettlementInCash	10142000
CY2022Q4	bbio	Potential Milestone Accrued Amount Settlement In Cash PotentialMilestoneAccruedAmountSettlementInCash	831000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1726000
CY2022Q4	bbio	Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion	2080000
CY2022Q4	bbio	Potential Milestone Fixed Monetary Settlement Amount PotentialMilestoneFixedMonetarySettlementAmount	173772000
CY2022Q4	bbio	Potential Milestone Accrued Settlement Amount PotentialMilestoneAccruedSettlementAmount	12627000
CY2021Q4	bbio	Accrued Termination Charges AccruedTerminationCharges	0
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	30569000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	29307000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3568000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3336000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	34137000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	32643000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5172000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5611000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3786000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	443000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	402000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6142000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4243000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	832000
CY2022	us-gaap	Lease Cost LeaseCost	11757000
CY2021	us-gaap	Lease Cost LeaseCost	10256000
CY2020	us-gaap	Lease Cost LeaseCost	4627000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	6245000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6122000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4169000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	423000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	272000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	34000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	240000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6380000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19595000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0596
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0558
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0662
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0662
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4495000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3971000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3938000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1869000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	850000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3355000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18478000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2529000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15949000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3675000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12274000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15949000
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2600000
CY2019Q4	bbio	One Time Fees Receivable Noncurrent OneTimeFeesReceivableNoncurrent	10000000.0
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	93828000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105574000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	58459000
CY2022	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	43800000
CY2022	us-gaap	Business Exit Costs1 BusinessExitCosts1	20739000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12720000
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	10306000
CY2022	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	43765000
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0
CY2022	bbio	Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod	2185000
CY2022	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	43765000
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	25232000
CY2022	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	13892000
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6826000
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6826000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-485079000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-586478000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-505488000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	427000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	24000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2020	us-gaap	Profit Loss ProfitLoss	-505488000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.217
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.256
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.250
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.039
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.033
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2022	bbio	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2038
CY2022	bbio	Research And Experimentation Expenditures Capital Account Amortized Period ResearchAndExperimentationExpendituresCapitalAccountAmortizedPeriod	P5Y
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	110000000.0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	199500000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	325830000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	331537000
CY2022Q4	bbio	Deferred Tax Assets Amortization Of Assets DeferredTaxAssetsAmortizationOfAssets	9172000
CY2021Q4	bbio	Deferred Tax Assets Amortization Of Assets DeferredTaxAssetsAmortizationOfAssets	9570000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5261000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	8833000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16134000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10233000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	86012000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	67724000
CY2022Q4	bbio	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	3075000
CY2021Q4	bbio	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	3821000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2391000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	77190000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	13154000
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	600000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	268000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	448000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	539087000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	432166000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	533929000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	423909000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5158000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8257000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	339000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2001000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2844000
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	3157000
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	5074000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5158000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8257000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017	bbio	Federal Net Operating Losses FederalNetOperatingLosses	37500000
CY2017	bbio	Federal Net Operating Losses Expiration Year FederalNetOperatingLossesExpirationYear	2035
CY2022	bbio	Federal Net Operating Losses FederalNetOperatingLosses	1400000000
CY2022	bbio	Percentage Of Taxable Income Limitation In Utilization Of Operating Loss Carry Forward PercentageOfTaxableIncomeLimitationInUtilizationOfOperatingLossCarryForward	0.80
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	95500000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21254000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12524000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	724000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	4037000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	354000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5035000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5047000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27013000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21254000
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022Q3	bbio	Percentage Of Corporate Alternative Minimum Tax Rate PercentageOfCorporateAlternativeMinimumTaxRate	0.15
CY2022Q3	bbio	Percentage Of Excise Tax Benefit On Corporate Stock Buy Back PercentageOfExciseTaxBenefitOnCorporateStockBuyBack	0.01
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	56406601
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	52252566
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29240319

Files In Submission

Name	View Source	Status
0000950170-23-004145-index-headers.html	Edgar Link	pending
0000950170-23-004145-index.html	Edgar Link	pending
0000950170-23-004145.txt	Edgar Link	pending
0000950170-23-004145-xbrl.zip	Edgar Link	pending
bbio-20221231.htm	Edgar Link	pending
bbio-20221231.xsd	Edgar Link	pending
bbio-ex10_16.htm	Edgar Link	pending
bbio-ex10_17.htm	Edgar Link	pending
bbio-ex10_18.htm	Edgar Link	pending
bbio-ex10_33.htm	Edgar Link	pending
bbio-ex21.htm	Edgar Link	pending
bbio-ex23_1.htm	Edgar Link	pending
bbio-ex31_1.htm	Edgar Link	pending
bbio-ex31_2.htm	Edgar Link	pending
bbio-ex32_1.htm	Edgar Link	pending
bbio-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img187071172_0.jpg	Edgar Link	pending
img187071172_1.jpg	Edgar Link	pending
img187071172_2.jpg	Edgar Link	pending
img187071172_3.jpg	Edgar Link	pending
bbio-20221231_cal.xml	Edgar Link	unprocessable
bbio-20221231_def.xml	Edgar Link	unprocessable
bbio-20221231_lab.xml	Edgar Link	unprocessable
bbio-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bbio-20221231_htm.xml	Edgar Link	completed
img187071172_4.jpg	Edgar Link	pending
img187071172_5.jpg	Edgar Link	pending
img187071172_6.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BBIO
BridgeBio Pharma, Inc. Stock $bbio

2023 Q1 Form 10-K Financial Statement

#000095017023004145 Filed on February 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BBIO BridgeBio Pharma, Inc. Stock $bbio

2023 Q1 Form 10-K Financial Statement

#000095017023004145 Filed on February 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BBIO
BridgeBio Pharma, Inc. Stock $bbio